Abnormalities of the somatotrophic axis in the obese agouti mouse

International Journal of Obesity

Volumn 30, Issue 3, 2006, Pages 430-438

  Martin, N M ^a   Houston, P A ^a   Patterson, M ^a   Sajedi, A ^a   Carmignac, D F ^b   Ghatei, M A ^a   Bloom, S R ^a   Small, C J ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (United Kingdom)

Author keywords

Agouti; Ghrelin; Growth; Leptin; Melanocortin

Indexed keywords

GHRELIN; GROWTH HORMONE; INSULIN; LEPTIN; NEUROPEPTIDE Y; SOMATOMEDIN C; SOMATOSTATIN;

AGE DISTRIBUTION; ANIMAL TISSUE; ARCUATE NUCLEUS; ARTICLE; BODY HEIGHT; BODY WEIGHT; COMPARATIVE STUDY; CONTROLLED STUDY; GENE EXPRESSION; GROWTH HORMONE BLOOD LEVEL; GROWTH HORMONE SECRETING CELL; HYPERINSULINEMIA; HYPERLEPTINEMIA; HYPOTHALAMUS; IN SITU HYBRIDIZATION; MOUSE; MOUSE STRAIN; NONHUMAN; OBESITY; PRIORITY JOURNAL; RADIOIMMUNOASSAY; SEX DIFFERENCE; STATISTICAL SIGNIFICANCE; STRAIN DIFFERENCE; WILD TYPE;

ANIMALS; BIOMETRY; BODY WEIGHT; GENE EXPRESSION; GROWTH DISORDERS; GROWTH HORMONE; HYPOTHALAMUS; INSULIN; INSULIN-LIKE GROWTH FACTOR I; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LEPTIN; MALE; MELANOCYTE-STIMULATING HORMONES; MICE; MICE, INBRED C57BL; MICE, OBESE; OBESITY; PEPTIDE HORMONES; PITUITARY GLAND, ANTERIOR; RNA, MESSENGER; SIGNAL TRANSDUCTION; SOMATOSTATIN; STOMACH;

AGOUTI; ANIMALIA;

EID: 33644615796     PISSN: 03070565     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.ijo.0803076     Document Type: Article

References (59)

1. Schwartz MW, Woods SC, Porte Jr D, Seeley RJ, Baskin DG. Central nervous system control of food intake. Nature 2000; 404 (6778): 661-671.
2. Ollmann MM, Wilson BD, Yang YK, Kerns JA, Chen Y, Gantz I et al. Antagonism of central melanocortin receptors in vitro and in vivo by agouti-related protein. Science 1997; 278 (5335): 135-138.
3. Rossi M, Kim MS, Morgan DG, Small CJ, Edwards CM, Sunter D et al. A C-terminal fragment of Agouti-related protein increases feeding and antagonizes the effect of alpha-melanocyte stimulating hormone in vivo. Endocrinology 1998; 139 (10): 4428-4431.
4. Graham M, Shutter JR, Sarmiento U, Sarosi I, Stark KL. Overexpression of Agrt leads to obesity in transgenic mice. Nat Genet 1997; 17 (3): 273-274.
5. Yaswen L, Diehl N, Brennan MB, Hochgeschwender U. Obesity in the mouse model of pro-opiomelanocortin deficiency responds to peripheral melanocortin. Nat Med 1999; 5 (9): 1066-1070.
6. Huszar D, Lynch CA, Fairchild-Huntress V, Dunmore JH, Fang Q, Berkemeier LR et al. Targeted disruption of the melanocortin-4 receptor results in obesity in mice. Cell 1997; 88 (1): 131-141.
7. Farooqi IS, Keogh JM, Yeo GS, Lank EJ, Cheetham T, O'Rahilly S. Clinical spectrum of obesity and mutations in the melanocortin 4 receptor gene. N Engl J Med 2003; 348 (12): 1085-1095.
8. Farooqi IS, Yeo GS, Keogh JM, Aminian S, Jebb SA, Butler G et al. Dominant and recessive inheritance of morbid obesity associated with melanocortin 4 receptor deficiency. J Clin Invest 2000; 106 (2): 271-279.
9. Krude H, Biebermann H, Schnabel D, Tansek MZ, Theunissen P, Mullis PE et al. Obesity due to proopiomelanocortin deficiency: three new cases and treatment trials with thyroid hormone and ACTH4-10. J Clin Endocrinol Metab 2003; 88 (10): 4633-4640.
10. Watanobe H, Yoneda M. Evaluation of the role of melanocortin 3 and 4 receptors in leptin-stimulated and spontaneous growth hormone secretion in rats. Neuroendocrinology 2003; 78 (6): 331-338.
11. Raposinho PD, Castillo E, d'Alleves V, Broqua P, Pralong FP, Aubert ML. Chronic blockade of the melanocortin 4 receptor subtype leads to obesity independently of neuropeptide Y action, with no adverse effects on the gonadotropic and somatotropic axes. Endocrinology 2000; 141 (12): 4419-4427.
12. Raposinho PD, White RB, Aubert ML. The melanocortin agonist Melanotan-II reduces the orexigenic and adipogenic effects of neuropeptide Y (NPY) but does not affect the NPY-driven suppressive effects on the gonadotropic and somatotropic axes in the male rat. J Neuroendocrinol 2003; 15 (2): 173-181.
13. Le Roith D, Bondy C, Yakar S, Liu JL, Butler A. The somatomedin hypothesis: 2001. Endocr Rev 2001; 22 (1): 53-74.
14. Muller EE, Locatelli V, Cocchi D. Neuroendocrine control of growth hormone secretion. Physiol Rev 1999; 79 (2): 511-607.
15. Wren AM, Small CJ, Ward HL, Murphy KG, Dakin CL, Taheri S et al. The novel hypothalamic peptide ghrelin stimulates food intake and growth hormone secretion. Endocrinology 2000; 141 (11): 4325-4328.
16. Wren AM, Seal LJ, Cohen MA, Brynes AE, Frost GS, Murphy KG et al. Ghrelin enhances appetite and increases food intake in humans. J Clin Endocrinol Metab 2001; 86 (12): 5992.
17. Erickson JC, Hollopeter G, Palmiter RD. Attenuation of the obesity syndrome of ob/ob mice by the loss of neuropeptide Y. Science 1996; 274 (5293): 1704-1707.
18. Steppan CM, Crawford DT, Chidsey-Frink KL, Ke H, Swick AG. Leptin is a potent stimulator of bone growth in ob/ob mice. Regul Pept 2000; 92 (1-3): 73-78.
19. Maor G, Rochwerger M, Segev Y, Phillip M. Leptin acts as a growth factor on the chondrocytes of skeletal growth centers. J Bone Miner Res 2002; 17 (6): 1034-1043.
20. Catzeflis C, Pierroz DD, Rohner-Jeanrenaud F, Rivier JE, Sizonenko PC, Aubert ML. Neuropeptide Y administered chronically into the lateral ventricle profoundly inhibits both the gonadotropic and the somatotropic axis in intact adult female rats. Endocrinology 1993; 132 (1): 224-234.
21. Raposinho PD, Pierroz DD, Broqua P, White RB, Pedrazzini T, Aubert ML. Chronic administration of neuropeptide Y into the lateral ventricle of C57BL/6J male mice produces an obesity syndrome including hyperphagia, hyperleptinemia, insulin resistance, and hypogonadism. Mol Cell Endocrinol 2001; 185 (1-2): 195-204.
22. Gao Q, Wolfgang MJ, Neschen S, Morino K, Horvath TL, Shulman GI et al. Disruption of neural signal transducer and activator of transcription 3 causes obesity, diabetes, infertility, and thermal dysregulation. Proc Natl Acad Sci USA 2004; 101 (13): 4661-4666.
23. Lu D, Willard D, Patel IR, Kadwell S, Overton L, Kost T et al. Agouti protein is an antagonist of the melanocyte-stimulating-hormone receptor. Nature 1994; 371 (6500): 799-802.
24. Wren AM, Small CJ, Fribbens CV, Neary NM, Ward HL, Seal LJ et al. The hypothalamic mechanisms of the hypophysiotropic action of ghrelin. Neuroendocrinology 2002; 76 (5): 316-324.
25. Beak SA, Small CJ, Ilovaiskaia I, Hurley JD, Ghatei MA, Bloom SR et al. Glucagon-like peptide-1 (GLP-1) releases thyrotropin (TSH): characterization of binding sites for GLP-1 on alpha-TSH cells. Endocrinology 1996; 137 (10): 4130-4138.
26. Carmignac DF, Gabrielsson BG, Robinson IC. Growth hormone binding protein in the rat: effects of gonadal steroids. Endocrinology 1993; 133 (6): 2445-2452.
27. Martin NM, Small CJ, Sajedi A, Patterson M, Ghatei MA, Bloom SR. Pre-obese and obese agouti mice are sensitive to the anorectic effects of peptide YY(3-36) but resistant to ghrelin. Int J Obes Relat Metab Disord 2004; 28 (7): 886-893.
28. Bennett PA, Levy A, Sophokleous S, Robinson IC, Lightman SL. Hypothalamic GH receptor gene expression in the rat: effects of altered GH status. J Endocrinol 1995; 147 (2): 225-234.
29. Wells SE, Flavell DM, Bisset GW, Houston PA, Christian H, Fairhall KM et al. Transgenesis and neuroendocrine physiology: a transgenic rat model expressing growth hormone in vasopressin neurones. J Physiol 2003; 551 (Part 1): 323-336.
30. Wells T, Houston PA. Skeletal growth acceleration with growth hormone secretagogues in transgenic growth retarded rats: pattern-dependent effects and mechanisms of desensitization. J Neuroendocrinol 2001; 13 (6): 496-504.
31. Yen TT, Greenberg MM, Yu PL, Pearson DV. An analysis of the relationships among obesity, plasma insulin and hepatic lipogenic enzymes in 'viable yellow obese' mice (Avy/a). Horm Metab Res 1976; 8 (3): 159-166.
32. Maffei M, Halaas J, Ravussin E, Pratley RE, Lee GH, Zhang Y et al. Leptin levels in human and rodent: measurement of plasma leptin and ob RNA in obese and weight-reduced subjects. Nat Med 1995; 1 (11): 1155-1161.
33. Correia ML, Haynes WG, Rahmouni K, Morgan DA, Sivitz WI, Mark AL. The concept of selective leptin resistance: evidence from agouti yellow obese mice. Diabetes 2002; 51 (2): 439-442.
34. Heston WE, Vlahakis G. Influence of the Ay gene on mammary-gland tumours, hepatomas and normal growth in mice. J Nat Cancer Inst 1961; 26: 969-983.
35. Wolff GL, Kodell RL, Kaput JA, Visek WJ. Caloric restriction abolishes enhanced metabolic efficiency induced by ectopic agouti protein in yellow mice. Proc Soc Exp Biol Med 1999; 221 (2): 99-104.
36. Mendel VE. Influence of the insulin-to-growth hormone ratio on body composition of mice. Am J Physiol 1980; 238 (3): E231-E234.
37. Tschop M, Weyer C, Tataranni PA, Devanarayan V, Ravussin E, Heiman ML. Circulating ghrelin levels are decreased in human obesity. Diabetes 2001; 50 (4): 707-709.
38. Batterham RL, Cohen MA, Ellis SM, Le Roux CW, Withers DJ, Frost GS et al. Inhibition of food intake in obese subjects by peptide YY3-36. N Engl J Med 2003; 349 (10): 941-948.
39. Haqq AM, Farooqi IS, O'Rahilly S, Stadler DD, Rosenfeld RG, Pratt KL et al. Serum ghrelin levels are inversely correlated with body mass index, age, and insulin concentrations in normal children and are markedly increased in Prader-Willi syndrome. J Clin Endocrinol Metab 2003; 88 (1): 174-178.
40. Kesterson RA, Huszar D, Lynch CA, Simerly RB, Cone RD. Induction of neuropeptide Y gene expression in the dorsal medial hypothalamic nucleus in two models of the agouti obesity syndrome. Mol Endocrinol 1997; 11 (5): 630-637.
41. Broberger C, De Lecea L, Sutcliffe JG, Hokfelt T. Hypocretin/orexin- and melanin-concentrating hormone-expressing cells form distinct populations in the rodent lateral hypothalamus: relationship to the neuropeptide Y and agouti gene-related protein systems. J Comp Neurol 1998; 402 (4): 460-474.
42. Hahn TM, Breininger JF, Baskin DG, Schwartz MW. Coexpression of Agrp and NPY in fasting-activated hypothalamic neurons. Nat Neurosci 1998; 1 (4): 271-272.
43. Tsuruta Y, Yoshimatsu H, Hidaka S, Kondou S, Okamoto K, Sakata T. Hyperleptinemia in A(y)/a mice upregulates arcuate cocaine-and amphetamine-regulated transcript expression. Am J Physiol Endocrinol Metab 2002; 282 (4): E967-E973.
44. Rettori V, Milenkovic L, Aguila MC, McCann SM. Physiologically significant effect of neuropeptide Y to suppress growth hormone release by stimulating somatostatin discharge. Endocrinology 1990; 126 (5): 2296-2301.
45. Korbonits M, Little JA, Forsling ML, Tringali G, Costa A, Navarra P et al. The effect of growth hormone secretagogues and neuropeptide Y on hypothalamic hormone release from acute rat hypothalamic explants. J Neuroendocrinol 1999; 11 (7): 521-528.
46. Nguyen-Yamamoto L, Deal CL, Finkelstein JA, Van Vliet G. Hormonal control of growth in the genetically obese Zucker rat. I. Linear growth, plasma insulin-like growth factor-I (IGF-I) and IGF-binding proteins. Endocrinology 1994; 134 (3): 1382-1388.
47. De Schepper JA, Smitz JP, Zhou XL, Louis O, Velkeniers BE, Vanhaelst L. Cafeteria diet-induced obesity is associated with a low spontaneous growth hormone secretion and normal plasma insulin-like growth factor-I concentrations. Growth Horm IGF Res 1998; 8 (5): 397-401.
48. Johnson TR, Blossey BK, Denko CW, Ilan J. Expression of insulin-like growth factor I in cultured rat hepatocytes: effects of insulin and growth hormone. Mol Endocrinol 1989; 3 (3): 580-587.
49. Yasunaga T, Furukawa S, Katsumata N, Horikawa R, Tanaka T, Tanae A et al. Nutrition related hormonal changes in obese children. Endocr J 1998; 45 (2): 221-227.
50. Frigeri LG, Wolff GL, Teguh C. Differential responses of yellow Avy/A and agouti A/a (BALB/c X VY) F1 hybrid mice to the same diets: glucose tolerance, weight gain, and adipocyte cellularity. Int J Obes Relat Metab Disord 1988; 12 (4): 305-320.
51. Levin BE. Arcuate NPY neurons and energy homeostasis in diet-induced obese and resistant rats. Am J Physiol 1999; 276 (2) (Part 2): R382-R387.
52. Levin BE, Dunn-Meynell AA. Reduced central leptin sensitivity in rats with diet-induced obesity. Am J Physiol Regul Integr Comp Physiol 2002; 283 (4): R941-R948.
53. Zhou X, De Schepper J, Vergeylen A, Luis O, Delhase M, Hooghe-Peters EL. Cafeteria diet-induced obese rats have an increased somatostatin protein content and gene expression in the periventricular nucleus. J Endocrinol Invest 1997; 20 (5): 264-269.
54. Schwartz MW, Baskin DG, Bukowski TR, Kuijper JL, Foster D, Lasser G et al. Specificity of leptin action on elevated blood glucose levels and hypothalamic neuropeptide Y gene expression in ob/ob mice. Diabetes 1996; 45 (4): 531-535.
55. Carro E, Senaris RM, Seoane LM, Frohman LA, Arimura A, Casanueva FF et al. Role of growth hormone (GH)-releasing hormone and somatostatin on leptin-induced GH secretion. Neuroendocrinology 1999; 69 (1): 3-10.
56. Bagnol D, Lu XY, Kaelin CB, Day HE, Ollmann M, Gantz I et al. Anatomy of an endogenous antagonist: relationship between Agouti-related protein and proopiomelanocortin in brain. J Neurosci 1999; 19 (18): RC26.
57. Mountjoy KG, Mortrud MT, Low MJ, Simerly RB, Cone RD. Localization of the melanocortin-4 receptor (MC4-R) in neuroendocrine and autonomic control circuits in the brain. Mol Endocrinol 1994; 8 (10): 1298-1308.
58. Butler AA, Kesterson RA, Khong K, Cullen MJ, Pelleymounter MA, Dekoning J et al. A unique metabolic syndrome causes obesity in the melanocortin-3 receptor-deficient mouse. Endocrinology 2000; 141 (9): 3518-3521.
59. Chen AS, Marsh DJ, Trumbauer ME, Frazier EG, Guan XM, Yu H et al. Inactivation of the mouse melanocortin-3 receptor results in increased fat mass and reduced lean body mass. Nat Genet 2000; 26 (1): 97-102.